⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2600862 | 1.00 | — | — | |
| SCHEMBL516204 | 1.00 | — | — | |
| Hydrochloric Acid SCHEMBL28657288 | 0.98 | TGFBR1 (0.39) | — | |
| Hydrochloric Acid SCHEMBL30478822 | 0.98 | TGFBR1 (0.39) | — | |
| SCHEMBL5195954 | 0.86 | MME (0.35) | — | |
| SCHEMBL19323313 | 0.84 | — | — | |
| SCHEMBL12155238 | 0.83 | SMN1; SMN2 (0.39) | — | |
| SCHEMBL11962066 | 0.83 | SMN1; SMN2 (0.39) | — | |
| SCHEMBL14224834 | 0.83 | SMN1; SMN2 (0.39) | — | |
| SCHEMBL8582497 | 0.82 | TGFBR1 (0.38) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4724457-A2 | RADIOPHARMACEUTICAL COMPOSITIONS TARGETING GLYPICAN-3 AND USES THEREOF | Rayzebio, Inc. (US) | 2026-04-15 | — | — | EP | disclosed |
| EP-4724459-A1 | PEPTIDE COMPOSITIONS TARGETING GLYPICAN-3 AND USES THEREOF | Peptidream Inc (JP) | 2026-04-15 | — | — | EP | disclosed |
| US-20260001914-A1 | MACROCYCLIC PEPTIDES TARGETING KRAS | MERCK SHARP & DOHME LLC (US) | 2026-01-01 | — | — | US | disclosed |
| WO-2024254339-A9 | RADIOPHARMACEUTICAL COMPOSITIONS TARGETING GLYPICAN-3 AND USES THEREOF | RAYZEBIO, INC. (US) | 2025-10-16 | — | — | WO | disclosed |
| WO-2024254339-A2 | RADIOPHARMACEUTICAL COMPOSITIONS TARGETING GLYPICAN-3 AND USES THEREOF | RAYZEBIO, INC. (US) | 2024-12-12 | — | — | WO | disclosed |
| WO-2024252336-A1 | PEPTIDE COMPOSITIONS TARGETING GLYPICAN-3 AND USES THEREOF | PEPTIDREAM INC. (JP) | 2024-12-12 | — | — | WO | disclosed |
| US-20230158179-A1 | RADIOPHARMACEUTICAL CONJUGATE COMPOSITIONS AND USES THEREOF | RAYZEBIO, INC. | 2023-05-25 | — | — | US | disclosed |
| US-20230158179-A1 | RADIOPHARMACEUTICAL CONJUGATE COMPOSITIONS AND USES THEREOF | RAYZEBIO, INC. | 2023-05-25 | — | — | US | disclosed |
| US-20230151060-A1 | CYCLIC PEPTIDE COMPOUND HAVING KRAS INHIBITORY ACTION | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2023-05-18 | — | — | US | disclosed |
| WO-2023283523-A1 | 2,3-DIHYDROBENZO[B][L,4]DIOXIN-6-YL CONTAINING COMPOUNDS USEFUL AS IMMUNOMODULATORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2023-01-12 | — | — | WO | disclosed |
| US-20140018577-A1 | Process for Preparing Lacosamide | UCB PHARMA GMBH (DE) | 2014-01-16 | — | — | US | disclosed |
| US-20130310373-A1 | PYRIMIDINE COMPOUND | ASTELLAS PHARMA INC. (JP) | 2013-11-21 | — | — | US | disclosed |
| US-8524727-B2 | Pyrimidine compound | ASTELLAS PHARMA INC. (JP) | 2013-09-03 | — | — | US | disclosed |
| US-8524727-B2 | Pyrimidine compound | ASTELLAS PHARMA INC. (JP) | 2013-09-03 | — | — | US | disclosed |
| US-20120028905-A1 | Isolation, Purification, and Structure Elucidation of the Antiproliferative Compound Coibamide A | The State of Oregon, Acting by and through the State Board of Higher Education on behalf of | 2012-02-02 | — | — | US | disclosed |
| US-8034780-B2 | Isolation, purification, and structure elucidation of the antiproliferative compound coibamide A | SMITHSONIAN TROPICAL RESEARCH INSTITUTE | 2011-10-11 | — | — | US | disclosed |
| US-20110053912-A1 | PYRIMIDINE COMPOUND | ASTELLAS PHARMA INC. (JP) | 2011-03-03 | — | — | US | disclosed |
| US-20110053912-A1 | PYRIMIDINE COMPOUND | ASTELLAS PHARMA INC. (JP) | 2011-03-03 | — | — | US | disclosed |
| US-20090023642-A1 | Isolation, Purification, and Structure Elucidation of the Antiproliferative Compound Coibamide A | THE STATE OF OREGON, ACTING BY AND THROUGH THE STATE BOARD OF HIGHER EDUCATION ON BEHALF OF OREGON STATE UNIVERSITY | 2009-01-22 | — | — | US | disclosed |
| EP-0308983-A2 | NMR imaging with Mn(II) coordination compositions | SALUTAR, INC. (US) | 1989-03-29 | — | — | EP | disclosed |